Due to the fact that normal prostate cells and prostate cancer cells express the highest levels of PSMA in the body, the overall expression profile is highly favorable and renders low molecular weight inhibitors of PSMA suitable for the diagnosis and therapy of prostate cancer. The gene discussed is FOLH1; the disease is Familial prostate cancer.